Sign in
Taking people in United StatesPhase 2

Pregnenolone for the Treatment of Alcohol Use Disorder

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
8 Jan 2024
Expected to end
31 Jul 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pregnenolone
  • Placebo
Record updated
2 February 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Male and females, aged 18-70 years
  • Regular weekly use of alcohol at least 3X weekly or more at treatment entry
  • Must meet current DSM-5 criteria for moderate to severe Alcohol Use Disorders (AUDs) using SCID-I for DSM-5
  • No health conditions that would impact trial participation as verified by screening and physical examination and absence of any of the exclusion criterions outlined below
  • Able to read English and complete study evaluations
  • Able to provide informed written and verbal consent

Who cannot take part

  • Regular use of anticonvulsants, sedatives or hypnotics, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), topiramate, baclofen
  • Regular use of steroidal supplements and steroid medications interacting with study medications based on clinical judgement of study physician (excluding hormonal contraceptives in women)
  • Meet current criteria for moderate to severe substance use disorders from use of any other psychoactive substance, excluding nicotine and cannabis use disorder
  • Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study, but stable, prescribed anti-hypertensives. cardiovascular and diabetes medications will be allowed after review by study physician
  • Any psychotic disorder or current Axis I psychiatric disorders requiring specific acute attention, including need for psychiatric medications, but stable, prescribed antidepressants and anti-anxiety medication to treat co-occurring psychiatric disorders will be allowed
  • Current use of opioids
  • Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)
  • Women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by urine pregnancy tests during initial medical evaluation, and assessed every two weeks during the course of the study)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in United States.

  • The Yale Stress Center: Yale UniversityNew Haven, United StatesContact: Rachel Hart, MSTaking people

About the trial

What the trial wants to find out

This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).

The 2 groups in the trial

  • patients receiving 300mg PREGExisting treatment, for comparison

    Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.

    Treatment: Pregnenolone

  • placeboPlacebo, for comparison

    Patients randomly assigned to receive a placebo daily.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT05781009, who can take part
Record updated
2 February 2026